Display options
Cite
Elmariah S, Fifer MA. Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction. Curr Treat Options Cardiovasc Med. 2012;14(6):665-78doi: 10.1007/s11936-012-0206-5.
Elmariah, S., & Fifer, M. A. (2012). Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction. Current treatment options in cardiovascular medicine, 14(6), 665-78. https://doi.org/10.1007/s11936-012-0206-5
Elmariah, Sammy, and Fifer, Michael A. "Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction." Current treatment options in cardiovascular medicine vol. 14,6 (2012): 665-78. doi: https://doi.org/10.1007/s11936-012-0206-5
Elmariah S, Fifer MA. Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction. Curr Treat Options Cardiovasc Med. 2012 Dec;14(6):665-78. doi: 10.1007/s11936-012-0206-5. PMID: 22956194.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Cardiovasc Med. 2012 Dec;14(6):665-78. doi: 10.1007/s11936-012-0206-5.

Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction.

Current treatment options in cardiovascular medicine

Sammy Elmariah, Michael A Fifer

Affiliations

  1. Cardiology Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, GRB-800, Boston, MA, 02114, USA.

PMID: 22956194 DOI: 10.1007/s11936-012-0206-5

Abstract

OPINION STATEMENT: Patients with hypertrophic cardiomyopathy (HCM) are classified as having hypertrophic obstructive cardiomyopathy (HOCM) if a left ventricular outflow tract (LVOT) gradient is present at rest or during provocation, as with Valsalva maneuver or exercise. Management of HCM in general and HOCM in particular encompasses (1) activity restriction with avoidance of volume depletion, (2) prevention of sudden cardiac death, (3) control of symptoms, and (4) screening of relatives. Those patients at high risk of sudden cardiac death (SCD) should be offered an implantable cardioverter-defibrillator (ICD). Pharmacologic treatment of symptoms in patients with HOCM consists of negative inotropic drugs, namely beta blockers, and disopyramide; a nondihydropyridine calcium channel blocker (CCB), usually verapamil, may be used in patients with noncardiac side-effects of beta blockers. Patients who have a dual-chamber pacemaker (PM) or ICD should undergo a trial of pacing with short atrioventricular (AV) delay. For patients with intolerable symptoms despite optimal conservative therapy, septal reduction therapy (SRT) should be considered and should be performed by experienced operators in institutions with multidisciplinary HCM programs. Younger patients with extreme hypertrophy are usually offered septal myectomy, while older patients, and those with important comorbidities are usually directed to alcohol septal ablation (ASA). For patients for whom either therapy is appropriate, there should be a balanced discussion with the patients of the benefits and risks of the 2 procedures.

References

  1. J Am Coll Cardiol. 2010 Feb 23;55(8):823-34 - PubMed
  2. J Am Coll Cardiol. 2005 Apr 19;45(8):1251-8 - PubMed
  3. J Am Coll Cardiol. 2011 Nov 22;58(22):2313-21 - PubMed
  4. Am J Cardiol. 2006 Jan 15;97(2):264-9 - PubMed
  5. Am J Cardiol. 2011 Aug 15;108(4):614 - PubMed
  6. Ann Noninvasive Electrocardiol. 2005 Oct;10(4 Suppl):67-83 - PubMed
  7. Circulation. 2011 Jan 18;123(2):e5-7 - PubMed
  8. N Engl J Med. 2012 Jan 12;366(2):130-40 - PubMed
  9. Circulation. 2011 Dec 13;124(24):e783-831 - PubMed
  10. Eur J Cardiothorac Surg. 2011 Dec;40(6):1515-20 - PubMed
  11. Herz. 2006 Dec;31(9):871-6 - PubMed
  12. JACC Cardiovasc Interv. 2011 Sep;4(9):1030-4 - PubMed
  13. Circulation. 1962 Aug;26:161-5 - PubMed
  14. Circ Cardiovasc Interv. 2010 Apr;3(2):97-104 - PubMed
  15. JACC Cardiovasc Interv. 2011 Jun;4(6):704-9 - PubMed
  16. Circulation. 2004 Jun 8;109(22):2807-16 - PubMed
  17. Int J Cardiovasc Imaging. 2012 Aug;28(6):1375-84 - PubMed
  18. Circ Cardiovasc Interv. 2011 Jun;4(3):256-65 - PubMed
  19. Circulation. 2010 Sep 14;122(11):1130-3 - PubMed
  20. Arch Cardiovasc Dis. 2011 Aug;104(8-9):444-9 - PubMed
  21. Circulation. 2011 Mar 15;123(10):e269-367 - PubMed
  22. Europace. 2011 Mar;13(3):355-61 - PubMed
  23. Am J Cardiol. 2010 Nov 15;106(10):1481-6 - PubMed
  24. Heart Rhythm. 2011 Feb;8(2):221-7 - PubMed
  25. J Am Coll Cardiol. 2011 Dec 6;58(24):2501-10 - PubMed
  26. Am J Cardiol. 2005 Mar 1;95(5):675-8 - PubMed
  27. Catheter Cardiovasc Interv. 2011 Aug 1;78(2):316-23 - PubMed
  28. Catheter Cardiovasc Interv. 2012 Nov 15;80(6):991-4 - PubMed
  29. J Interv Cardiol. 2011 Feb;24(1):77-84 - PubMed
  30. J Am Coll Cardiol. 2011 Nov 22;58(22):2322-8 - PubMed
  31. Circulation. 2008 Jan 22;117(3):429-39 - PubMed
  32. Heart. 2012 Jan;98(2):116-25 - PubMed
  33. Heart. 2011 Oct;97(20):1718-9 - PubMed
  34. Am J Cardiol. 1994 Aug 15;74(4):405-8 - PubMed
  35. Circulation. 2001 Nov 20;104(21):2517-24 - PubMed
  36. J Thorac Cardiovasc Surg. 2012 Feb;143(2):303-9 - PubMed
  37. Circulation. 2010 Oct 19;122(16):1562-9 - PubMed
  38. Am J Physiol Heart Circ Physiol. 2011 Jul;301(1):H129-37 - PubMed
  39. Circulation. 2008 Jul 8;118(2):131-9 - PubMed
  40. J Thorac Cardiovasc Surg. 2011 Feb;141(2):439-43 - PubMed
  41. N Engl J Med. 1997 Mar 13;336(11):775-85 - PubMed
  42. Am Heart J. 2007 Nov;154(5):899-907 - PubMed
  43. Eur Heart J. 2011 May;32(9):1059-64 - PubMed
  44. J Am Coll Cardiol. 2011 Feb 1;57(5):572-6 - PubMed
  45. Circulation. 2011 Aug 16;124(7):857-63 - PubMed
  46. Am J Cardiol. 1978 Dec;42(6):993-1001 - PubMed
  47. Am J Cardiol. 2010 Nov 1;106(9):1307-12 - PubMed
  48. J Thorac Cardiovasc Surg. 2011 Jul;142(1):53-9 - PubMed

Publication Types